GlassScriptPhysician profile
Rajan Senguttuvan
NPI 1740543396
$3,560.27
in general payments reported to CMS, 2019-2025
26 companies · $32.56 in 2025
The $32.56 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $360 · 2021: $602 · 2022: $576 · 2023: $974 · 2024: $601 · 2025: $32.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $690.44 | 2019-2025 | Sogroya, Norditropin |
| Abbvie INC. | $501.26 | 2019-2024 | Lupron Depot |
| Ascendis Pharma Endocrinology INC | $439.84 | 2022-2024 | |
| Insulet Corporation | $187.16 | 2019-2024 | Omnipod |
| Dexcom, INC. | $162.84 | 2021-2024 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $158.63 | 2019 | |
| Medtronic, INC. | $154.94 | 2021-2024 | Minimed 780g |
| Abbott Laboratories | $141.51 | 2020-2024 | Freestyle Libre |
| Tandem Diabetes Care, INC. | $136.52 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Biomarin Pharmaceutical INC. | $125.13 | 2022-2023 | Voxzogo 1.2mg |
| Tolmar Pharmaceuticals, INC. | $122.52 | 2020-2022 | |
| Pfizer INC. | $115.79 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $103.69 | 2019-2022 | |
| Tolmar, INC. | $81.87 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $81.13 | 2020-2023 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eton Pharmaceuticals, INC. | $60.01 | 2021-2024 | Alkindi |
| Ferring Pharmaceuticals INC. | $56.23 | 2019-2020 | |
| Lilly USA, LLC | $54.12 | 2019-2020 | |
| Kyowa Kirin, INC. | $46.27 | 2023-2024 | Crysvita |
| Ipsen Biopharmaceuticals, INC | $30.04 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.55 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $20.78 | 2023 | Imcivree |
| Arbor Pharmaceuticals, INC. | $20.44 | 2022 | |
| Companion Medical, INC. | $16.46 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.82 | 2023 | Triptodur |
| Vistapharm, INC. | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajan Senguttuvan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.